PAHCNasdaqPharmaceutical PreparationsFiscal year ends June 30
PHIBRO ANIMAL HEALTH CORP
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Aug 26, 2026
$39.34+0.52 (+1.34%)
Close on Oct 19, 2026
- Market cap
- $1.61B
- P/E (TTM)
- 16.2
- Dividend yield
- 1.22%
PHIBRO ANIMAL HEALTH CORP revenue by segment
By business segment
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $1.16B | $962.80M | $706.48M | $659.85M | $607.06M | $545.72M | $526.90M | $531.97M | $531.73M | $497.75M | 76.6% | +20.7% |
| Mineral Nutrition | $282.34M | $253.24M | $243.66M | $242.66M | $259.51M | $220.56M | $214.41M | $233.78M | $234.92M | $218.30M | 18.6% | +11.5% |
| Performance Products | $73.53M | $80.18M | $67.53M | $75.38M | $75.69M | $67.07M | $59.04M | $62.24M | $53.33M | $48.24M | 4.8% | -8.3% |
By product or service
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Animal Health | $1.16B | $962.80M | $706.48M | $659.85M | $607.06M | $545.72M | – | – | – | – | 76.6% | +20.7% |
| MFAs and other | $810.73M | $646.35M | $420.96M | $387.35M | $361.54M | $330.02M | $322.30M | – | – | – | 53.4% | +25.4% |
| Mineral Nutrition | $282.34M | $253.24M | $243.66M | $242.66M | $259.51M | $220.56M | – | – | – | – | 18.6% | +11.5% |
| Nutritional Specialties | $195.07M | $179.29M | $164.67M | $172.50M | $157.20M | $142.76M | $129.26M | – | – | – | 12.8% | +8.8% |
| Vaccines | $156.42M | $137.15M | $120.85M | $100.00M | $88.32M | $72.94M | $75.34M | – | – | – | 10.3% | +14.0% |
| Performance Products | $73.53M | $80.18M | $67.53M | $75.38M | $75.69M | $67.07M | – | – | – | – | 4.8% | -8.3% |
By region
| Revenue | FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | % of revenue | YoY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United States | $877.13M | $739.92M | $584.76M | $578.77M | $561.80M | $494.89M | $471.94M | $480.10M | $490.88M | $483.79M | 57.8% | +18.5% |
| Latin America and Canada | $340.67M | $298.65M | $247.71M | $219.85M | $191.05M | $166.33M | $158.94M | $152.38M | $143.23M | $113.19M | 22.4% | +14.1% |
| Europe, Middle East and Africa | $187.94M | $160.23M | $121.98M | $117.82M | $122.48M | $114.13M | $112.18M | – | – | – | 12.4% | +17.3% |
| Asia Pacific | $112.36M | $97.42M | $63.23M | $61.46M | $66.93M | $58.01M | $57.30M | $90.15M | $75.49M | $71.46M | 7.4% | +15.3% |
| Israel | – | – | – | – | – | – | – | – | $109.22M | $92.75M | – | – |
| Europe and Africa | – | – | – | – | – | – | – | – | $43.90M | $40.21M | – | – |
| Europe, Middle East and Africa | – | – | – | – | – | $114.13M | $112.18M | $105.37M | $110.38M | $95.84M | – | – |
From the segment and revenue-disaggregation notes of Phibro Animal Health's 10-K and 10-Q filings (XBRL). Fourth-quarter figures are the fiscal year less the first nine months. Segment names follow the company's own labels and can change when it reorganizes.